Brokerages Set Roivant Sciences Ltd. (NASDAQ:ROIV) Target Price at $18.08

Roivant Sciences Ltd. (NASDAQ:ROIV) has been assigned an average recommendation of “Buy” from the seven analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $18.08.

Several equities research analysts have weighed in on the company. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a report on Thursday, January 30th. HC Wainwright restated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Tuesday, February 11th.

Insider Activity at Roivant Sciences

In related news, CIO Mayukh Sukhatme sold 412,584 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $12.05, for a total transaction of $4,971,637.20. Following the completion of the sale, the executive now directly owns 18,836,547 shares in the company, valued at approximately $226,980,391.35. The trade was a 2.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Rakhi Kumar sold 227,500 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the sale, the chief accounting officer now owns 163,264 shares of the company’s stock, valued at $1,702,843.52. The trade was a 58.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,288,170 shares of company stock worth $26,547,299. 7.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. purchased a new position in shares of Roivant Sciences during the 4th quarter worth $181,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Roivant Sciences by 4.5% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,411,466 shares of the company’s stock worth $28,528,000 after acquiring an additional 104,288 shares in the last quarter. Zimmer Partners LP acquired a new position in Roivant Sciences during the 4th quarter worth about $2,992,000. Vestal Point Capital LP acquired a new position in Roivant Sciences during the 4th quarter worth about $14,788,000. Finally, Vident Advisory LLC lifted its stake in Roivant Sciences by 98.7% during the 4th quarter. Vident Advisory LLC now owns 32,039 shares of the company’s stock worth $379,000 after acquiring an additional 15,918 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

Shares of ROIV stock opened at $10.52 on Friday. The company has a market cap of $7.51 billion, a P/E ratio of -70.13 and a beta of 1.25. The stock’s 50-day moving average is $11.17 and its 200 day moving average is $11.60. Roivant Sciences has a 1-year low of $9.76 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, analysts anticipate that Roivant Sciences will post -0.92 EPS for the current year.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.